Sona Nanotech (SONA) Stock Overview
Operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SONA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sona Nanotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.37 |
| 52 Week High | CA$0.91 |
| 52 Week Low | CA$0.24 |
| Beta | 0.67 |
| 1 Month Change | -5.13% |
| 3 Month Change | -22.11% |
| 1 Year Change | 23.33% |
| 3 Year Change | 117.65% |
| 5 Year Change | -80.21% |
| Change since IPO | 117.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| SONA | CA Life Sciences | CA Market | |
|---|---|---|---|
| 7D | 2.8% | -1.7% | -4.3% |
| 1Y | 23.3% | -4.2% | 35.3% |
Return vs Industry: SONA exceeded the Canadian Life Sciences industry which returned -4.2% over the past year.
Return vs Market: SONA underperformed the Canadian Market which returned 35.3% over the past year.
Price Volatility
| SONA volatility | |
|---|---|
| SONA Average Weekly Movement | 11.9% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 10.8% |
| 10% most volatile stocks in CA Market | 19.9% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: SONA has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: SONA's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | David Regan | www.sonanano.com |
Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therapy for the treatment of cancer tumors; and diagnostic tools comprising lateral flow assay rapid and bovine tuberculosis tests. The company was founded in 2013 and is based in Halifax, Canada.
Sona Nanotech Inc. Fundamentals Summary
| SONA fundamental statistics | |
|---|---|
| Market cap | CA$41.18m |
| Earnings (TTM) | -CA$3.25m |
| Revenue (TTM) | n/a |
Is SONA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SONA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.25m |
| Earnings | -CA$3.25m |
Last Reported Earnings
Oct 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -793.6% |
How did SONA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 21:51 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sona Nanotech Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Okunewitch | Maxim Group |